Spectrum of immune‐mediated inner ear disease and cochlear implant results

Malik, M. Shaheer; Pandian, Vinciya; Masood, Hamid; Diaz, David Achanccaray; Varela, Voss; Dávalos-Balderas, Alfredo José; Parra-Cárdenas, Martha; Seo, Philip; Francis, Howard W.

doi:10.1002/lary.23604

Cited by 28 publications

(29 citation statements)

References 26 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pathophysiology of inner ear involvement in systemic autoimmune diseases is still unclear and may be related to circulating antibodies against a number of inner ear antigens leading to antibody-dependent cell-mediated cytotoxicity, the activation of the complement system, a direct action of cytotoxic T cells, or immune complex-mediated damage [5, 7, 8, 10–14]. …”

Section: Inner Ear Involvement In Autoimmune Diseasesmentioning

confidence: 99%

“…There is growing interest for inner ear involvement in systemic autoimmune diseases [5, 6]; this condition should be considered in patients with audiovestibular dysfunction presenting a constellation of symptoms consistent with systemic autoimmunity or with a preexisting diagnosis of autoimmune disease [7, 8]. Inner ear involvement in systemic autoimmune diseases should be distinguished from primary autoimmune inner ear disease, a condition in which the immune response acts directly against the inner ear [6, 7].…”

Section: Introductionmentioning

confidence: 99%

“…Inner ear involvement in systemic autoimmune diseases should be distinguished from primary autoimmune inner ear disease, a condition in which the immune response acts directly against the inner ear [6, 7]. …”

Section: Introductionmentioning

confidence: 99%

“…Inner ear involvement in autoimmune diseases is estimated to account for less than 1% of all cases of acquired hearing loss [7] and follows gender and demographic characteristics of autoimmune disorders, with higher prevalence in female patients between their thirties and fifties [5]. …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Audiovestibular Symptoms in Systemic Autoimmune Diseases

Ralli

D’Aguanno

Stadio

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

Immune-mediated inner ear disease can be primary, when the autoimmune response is against the inner ear, or secondary. The latter is characterized by the involvement of the ear in the presence of systemic autoimmune conditions. Sensorineural hearing loss is the most common audiovestibular symptom associated with systemic autoimmune diseases, although conductive hearing impairment may also be present. Hearing loss may present in a sudden, slowly, rapidly progressive or fluctuating form, and is mostly bilateral and asymmetric. Hearing loss shows a good response to corticosteroid therapy that may lead to near-complete hearing restoration. Vestibular symptoms, tinnitus, and aural fullness can be found in patients with systemic autoimmune diseases; they often mimic primary inner ear disorders such as Menière's disease and mainly affect both ears simultaneously. Awareness of inner ear involvement in systemic autoimmune diseases is essential for the good response shown to appropriate treatment. However, it is often misdiagnosed due to variable clinical presentation, limited knowledge, sparse evidence, and lack of specific diagnostic tests. The aim of this review is to analyse available evidence, often only reported in the form of case reports due to the rarity of some of these conditions, of the different clinical presentations of audiological and vestibular symptoms in systemic autoimmune diseases.

show abstract

Section: Inner Ear Involvement In Autoimmune Diseasesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Audiovestibular Symptoms in Systemic Autoimmune Diseases

Ralli

D’Aguanno

Stadio

et al. 2018

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Results shown in this study, based on PTA, indicate that CI implanted in an ear with P-SNHL is an effective, safe measure to provide stable audibility from the first month of activation. This piece of information is extremely important for the group of patients with AHL because an objective of bimodal adaptations is to obtain better sound perception and ensure hearing through one of the ears, in case the contralateral ear may suffer some type of degenerative pathology, as could potentially be the case with bilateral Meniere's disease [15] , autoimmune hearing loss [16] , otoesclerosis [17] , or some labyrinth malformations [18] . The stable PTA results had already been described by other authors [19,20] , and their homogeneity, regardless of the initial HLs, can be explained by several reasons: 1.)…”

Section: Discussionmentioning

confidence: 99%

Bimodal Stimulation with Cochlear Implant and Hearing Aid in Cases of Highly Asymmetrical Hearing Loss

Sanhueza

Manrique²,

Huarte³

et al. 2016

Int Adv Otol

View full text Add to dashboard Cite

Intratympanic Lipopolysaccharide Elevates Systemic Fluorescent Gentamicin Uptake in the Cochlea

Chai

Yang

et al. 2021

The Laryngoscope

View full text Add to dashboard Cite

Objectives/Hypothesis Lipopolysaccharide (LPS), a key component of bacterial endotoxins, activates macrophages and triggers the release of inflammatory cytokines in mammalian tissues. Recent studies have shown that intratympanic injection of LPS simulates acute otitis media (AOM) and results in morphological and functional changes in the inner ear. Here we established an AOM mouse model with LPS to investigate the uptake of ototoxic gentamicin in the inner ear, and elucidated the underlying mechanism by focusing on cochlear inflammation as a result of AOM. Study Design Preclinical rodent animal model. Methods Fluorescently tagged gentamicin (GTTR) was systemically administered to mice with AOM. Iba1‐positive macrophage morphology and inner ear cytokine profile were evaluated by immunofluorescence technique and a mouse cytokine array kit, respectively. Results We observed characteristic symptoms of AOM in the LPS‐treated ears with elevated hearing thresholds indicating a conductive hearing loss. More importantly, the LPS‐induced AOM activated cochlear inflammatory responses, manifested by macrophage infiltration, particularly in the organ of Corti and the spiral ligament, in addition to the up‐regulation of proinflammatory cytokines. Meanwhile, GTTR uptake in the stria vascularis and sensory hair cells from all the LPS‐treated ears was significantly enhanced at 24, 48, and 72‐hour post‐treatment, as the most prominent enhancement was observed in the 48‐hour group. Conclusion In summary, this study suggests that the pathological cochlea is more susceptible to ototoxic drugs, including aminoglycosides, and justified the clinical concern of aminoglycoside ototoxicity in the AOM treatment. Laryngoscope, 131:E2573–E2582, 2021

show abstract

Spectrum of immune‐mediated inner ear disease and cochlear implant results

Cited by 28 publications

References 26 publications

Audiovestibular Symptoms in Systemic Autoimmune Diseases

Audiovestibular Symptoms in Systemic Autoimmune Diseases

Bimodal Stimulation with Cochlear Implant and Hearing Aid in Cases of Highly Asymmetrical Hearing Loss

Intratympanic Lipopolysaccharide Elevates Systemic Fluorescent Gentamicin Uptake in the Cochlea

Contact Info

Product

Resources

About